JPRN-UMIN000007108已完成未知
Anti-Muscarinic Agents Alone and in Combination With a Muscarinic Agonist in Subjects with Overactive Bladder(OAB) Symptoms - Anti-Muscarinic Agents Alone and in Combination With a Muscarinic Agonist in Subjects with Overactive Bladder(OAB) Symptoms
Department of Urology, Nihon University Itabashi Hospital0 个研究点目标入组 18 人开始时间: 2012年1月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)stress incontinence, insensate incontinence and overflow incontinence, as major reason for urine loss or urinary frequency as determined by the investigator 2)history of neurogenic bladder 3)uninvestigated hematuria 4)acute urinary tract infections during the anti-muscarinic baseline period or recurrent UTI defined as receiving treatment for symptomatic UTI more than 2 times in the past year 5)indwelling catheter or requiring intermittent catheterization 6)bladder or lower urinary tract surgeries performed within the past 6 months, or those who had surgeries leading to complications such as fistula 7)diagnosed with bladder cancer, interstitial cystitis, or painful bladder syndrome within the past 6 months 8)taking diuretics or estrogen therapy that was not part of a long-term stable program of at least 6 months 9)severe renal impairment (CLCR<30mL/min) 10)taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin 11)severe hepatic impairment 12)employing bladder retraining/bladder drill programs 13)Subjects who were anticipated to begin or change other bladder therapies (non-medicinal) such as biofeedback or kegels, during the course of the study 14)Subjects with malignancy within the past 6 months or prior pelvic malignancies requiring radiation therapy or whose surgery had led to complications such as fistulas, etc 15)diagnosed Sjogrens syndrome 16)History of tachyarrhythmias or cardiac disease 17)Any medications that may interfere with the subject's suitability and/or effective participation in the study 18)history or current untreated narrow angle glaucoma 19)history of myasthenia gravis 20)the known or suspected biliary tract disease, nephrolithiasis, cognitive or psychiatric disturbances 21)hypersensitivity toward Solifenacin or pilocarpine or to any excipient in their respective formulations 22)participating in another clinical trial or receiving a non-approved drug less than 30 days prior to screening
研究者
相似试验
尚未招募
不适用
Efficacy of long-acting muscarinic antagonist for chronic coughchronic coughJPRN-UMIN000023773Kyoto University60
已完成
2 期
Effects of noradrenergic and antimuscarinic agents on upper airway muscle activity during sleepACTRN12616000469415euroscience Research Australia (NeuRA)10
已完成
2 期
Effects of noradrenergic and antimuscarinic agents on obstructive sleep apnoea (OSA) and upper airway muscle activity during sleepACTRN12617001326381euroscience Research Australia (NeuRA)15
已完成
4 期
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1Bladder Outlet ObstructionNCT01661621Buddhist Tzu Chi General Hospital395
已完成
不适用
The efficacy and safety of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) in COPD patients with benign prostatic hyperplasia (BPH)JPRN-UMIN000009357Hamamatsu University School of Medicine30